Related Experiment Video
Updated: Jun 24, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Differences in cardiovascular risk profile based on relationship between post-load plasma glucose and fasting plasma
Elena Succurro1, Maria Adelaide Marini, Alessandro Grembiale
1Department of Experimental and Clinical Medicine, University Magna-Graecia of Catanzaro, Catanzaro, Italy.
Diabetes/Metabolism Research and Reviews
|March 26, 2009
Summary
Normal glucose tolerance subjects with elevated 2-h plasma glucose during an oral glucose tolerance test have an atherogenic profile, indicating increased cardiovascular disease risk.
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Cardiovascular Disease Risk
Background:
- Normal glucose tolerance (NGT) subjects with 2-h plasma glucose (PG) above fasting levels during an oral glucose tolerance test (OGTT) face higher type 2 diabetes risk.
- The atherogenic profile of these NGT individuals (Group II) compared to NGT individuals with normalized 2-h PG (Group I) remains unclear.
Purpose of the Study:
- To investigate whether NGT individuals with non-normalized 2-h PG during OGTT exhibit a more atherogenic profile than those with normalized 2-h PG.
- To assess cardiovascular risk factors and carotid intima-media thickness (IMT) in these two NGT groups.
Main Methods:
- Examined 266 non-diabetic offspring of type 2 diabetic patients from the EUGENE2 study.
- Assessed glucose tolerance and insulin sensitivity using euglycaemic-hyperinsulinemic clamp.
- Evaluated cardiovascular risk factors and measured carotid intima-media thickness (IMT).
Main Results:
- Group II subjects showed significantly higher waist circumference, blood pressure, triglycerides, and 2-h post-load PG compared to Group I.
- Group II also exhibited higher hs-C-reactive protein, interleukin-6, IGF-1, and IMT, alongside lower insulin sensitivity.
- These findings indicate a more atherogenic profile in NGT individuals with non-normalized 2-h PG during OGTT.
Conclusions:
- NGT subjects whose PG does not return to fasting levels within 2 h during OGTT possess an atherogenic profile.
- This suggests that detailed OGTT monitoring (e.g., 30-min intervals) can help identify cardiovascular disease risk in glucose-tolerant individuals.
Related Concept Videos
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:19Overview of Carbohydrate Metabolism
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...